MATULANE Drug Patent Profile
✉ Email this page to a colleague
When do Matulane patents expire, and when can generic versions of Matulane launch?
Matulane is a drug marketed by Leadiant Biosci Inc and is included in one NDA.
The generic ingredient in MATULANE is procarbazine hydrochloride. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the procarbazine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MATULANE?
- What are the global sales for MATULANE?
- What is Average Wholesale Price for MATULANE?
Summary for MATULANE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 107 |
| Clinical Trials: | 6 |
| Patent Applications: | 4,457 |
| Drug Prices: | Drug price information for MATULANE |
| What excipients (inactive ingredients) are in MATULANE? | MATULANE excipients list |
| DailyMed Link: | MATULANE at DailyMed |
Recent Clinical Trials for MATULANE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AIDS Malignancy Consortium | Phase 2 |
| The EMMES Corporation | Phase 2 |
| The Emmes Company, LLC | Phase 2 |
Pharmacology for MATULANE
| Drug Class | Alkylating Drug |
| Mechanism of Action | Alkylating Activity |
US Patents and Regulatory Information for MATULANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leadiant Biosci Inc | MATULANE | procarbazine hydrochloride | CAPSULE;ORAL | 016785-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MATULANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Leadiant Biosci Inc | MATULANE | procarbazine hydrochloride | CAPSULE;ORAL | 016785-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MATULANE
See the table below for patents covering MATULANE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 120758 | ⤷ Sign Up | |
| Sweden | 354653 | ⤷ Sign Up | |
| United Kingdom | 968460 | ⤷ Sign Up | |
| Switzerland | 441366 | Verfahren zur Herstellung von substituierten Hydrazinverbindungen | ⤷ Sign Up |
| Sweden | 354654 | ⤷ Sign Up | |
| Cyprus | 314 | Novel hydrazine derivatives and a process for the manufacture thereof | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
